These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 26451276)

  • 41. Impact of First-Line FOLFIRINOX-Induced Peripheral Neuropathy on the Efficacy of Second-Line GnP in Patients with Unresectable Advanced Pancreatic Cancer.
    Sadaka S; Iwashita T; Fujii H; Kato-Hayashi H; Ohata K; Uemura S; Shimizu M; Suzuki A
    J Clin Med; 2022 Oct; 11(19):. PubMed ID: 36233762
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Exceptional Response to Second-Line Gemcitabine/Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma.
    Bukhari N; Abdalla K; Ibnshamsa F; Alselwi W; Al-Shakir S; Alqahtani M
    Cureus; 2021 Oct; 13(10):e18756. PubMed ID: 34796055
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Real-World Outcomes of First-Line Chemotherapy in Metastatic Pancreatic Cancer: A Nationwide Population-Based Study in Korea.
    Park CS; Park BK; Han JH; Lee KJ; Son KJ
    Cancers (Basel); 2024 Sep; 16(18):. PubMed ID: 39335145
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nab-paclitaxel plus gemcitabine as first-line palliative chemotherapy in a patient with metastatic pancreatic cancer with Eastern Cooperative Oncology Group performance status of 2.
    Martín AJ; Alfonso PG; Rupérez AB; Jiménez MM
    Oncol Lett; 2016 Jul; 12(1):727-730. PubMed ID: 27347207
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients.
    Merz V; Cavaliere A; Messina C; Salati M; Zecchetto C; Casalino S; Milella M; Caffo O; Melisi D
    Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32366019
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors.
    Bauer TM; Patel MR; Forero-Torres A; George TJ; Assad A; Du Y; Hurwitz H
    Onco Targets Ther; 2018; 11():2399-2407. PubMed ID: 29750040
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer: a retrospective analysis.
    da Rocha Lino A; Abrahão CM; Brandão RM; Gomes JR; Ferrian AM; Machado MC; Buzaid AC; Maluf FC; Peixoto RD
    J Gastrointest Oncol; 2015 Oct; 6(5):511-5. PubMed ID: 26487945
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Folfirinox vs. Gemcitabine + Nab-Paclitaxel as the First-Line Treatment for Pancreatic Cancer: A Systematic Review and Meta-Analysis.
    Merza N; Farooqui SK; Dar SH; Varughese T; Awan RU; Qureshi L; Ansari SA; Qureshi H; Mcilvaine J; Vohra I; Nawras Y; Kobeissy A; Hassan M
    World J Oncol; 2023 Oct; 14(5):325-339. PubMed ID: 37869244
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evolving treatment landscape for early and advanced pancreatic cancer.
    Lau SC; Cheung WY
    World J Gastrointest Oncol; 2017 Jul; 9(7):281-292. PubMed ID: 28808501
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Somatic Mutation Profile as a Predictor of Treatment Response and Survival in Unresectable Pancreatic Ductal Adenocarcinoma Treated with FOLFIRINOX and Gemcitabine Nab-Paclitaxel.
    Paredes de la Fuente R; Sucre S; Ponce C; Rattani AAA; Peters MLB
    Cancers (Basel); 2024 Aug; 16(15):. PubMed ID: 39123462
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of relative dose intensity of nab-paclitaxel for the short-term outcomes, survival, and quality of life in patients with advanced pancreatic cancer: a retrospective study.
    Lian L; Shen XM; Huang TA; Li DP; Li XM; Han SG; Xu XF; Ma CT; Zhou C
    Transl Cancer Res; 2022 Jul; 11(7):2310-2320. PubMed ID: 35966303
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study.
    Otsuka T; Shirakawa T; Shimokawa M; Koga F; Kawaguchi Y; Ueda Y; Nakazawa J; Komori A; Otsu S; Arima S; Fukahori M; Okabe Y; Makiyama A; Taguchi H; Honda T; Shibuki T; Nio K; Ide Y; Mizuta T; Mitsugi K; Ureshino N
    Int J Clin Oncol; 2021 May; 26(5):941-950. PubMed ID: 33483857
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pancreatic INI1-deficient undifferentiated rhabdoid carcinoma achieves complete clinical response on gemcitabine and nab-paclitaxel following immediate progression on FOLFIRINOX: a case report.
    King DA; Rahalkar S; Bingham DB; Fisher GA
    J Gastrointest Oncol; 2021 Apr; 12(2):874-879. PubMed ID: 34012674
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sequential Treatment of Metastatic Adenocarcinoma of the Pancreatic Duct with Liver Metastasis Following the NAPOLI-1 Study Protocol with nal-Irinotecan plus 5-FU in the Second Line.
    Akhoundova Sanoyan D; Reiner CS; Papageorgiou P; Siebenhüner AR
    Case Rep Oncol; 2020; 13(1):79-84. PubMed ID: 32110224
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy.
    Tong YT; Lai Z; Katz MHG; Prakash LR; Wang H; Chatterjee D; Kim M; Tzeng CD; Lee JE; Ikoma N; Rashid A; Wolff RA; Zhao D; Koay EJ; Maitra A; Wang H
    Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174073
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Folfirinox
    Williet N; Saint A; Pointet AL; Tougeron D; Pernot S; Pozet A; Bechade D; Trouilloud I; Lourenco N; Hautefeuille V; Locher C; Desrame J; Artru P; Thirot Bidault A; Le Roy B; Pezet D; Phelip JM; Taieb J
    Therap Adv Gastroenterol; 2019; 12():1756284819878660. PubMed ID: 31598136
    [TBL] [Abstract][Full Text] [Related]  

  • 57. First-line chemotherapy in very elderly patients with metastatic pancreatic cancer: Gemcitabine monotherapy
    Han SY; Kim DU; Seol YM; Kim S; Lee NK; Hong SB; Seo HI
    World J Clin Cases; 2020 Sep; 8(18):4022-4033. PubMed ID: 33024759
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Head-to-head comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel in the neoadjuvant chemotherapy of localized pancreatic cancer: a systematic review and meta-analysis.
    Tang R; Meng Q; Wang W; Liang C; Hua J; Xu J; Yu X; Shi S
    Gland Surg; 2021 May; 10(5):1564-1575. PubMed ID: 34164301
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combination therapy with gemcitabine and nab-paclitaxel for locally advanced unresectable pancreatic cancer.
    Saito T; Ishido K; Kudo D; Kimura N; Wakiya T; Nakayama Y; Hakamada K
    Mol Clin Oncol; 2017 Jun; 6(6):963-967. PubMed ID: 28588798
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Head-to-head comparison of treatment sequences in advanced pancreatic cancer-Real-world data from the prospective German TPK clinical cohort study.
    Marschner N; Haug N; Hegewisch-Becker S; Reiser M; Dörfel S; Lerchenmüller C; Linde H; Wolf T; Hof A; Kaiser-Osterhues A; Potthoff K; Jänicke M;
    Int J Cancer; 2024 Jul; ():. PubMed ID: 38956837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.